New In MDS
Our "New in MDS" articles cover treatment option updates, coverage of advancements from MDS academic meetings, and more.
mds, aml, Bemcentinib, new in mds, life with mds, new treatment for HR-MDS
Immunosuppressive therapy can be an option for patients with lower-risk MDS (LR-MDS). A common type of immunotherapy for MDS is antithymocyte globulin (ATG).
Reblozyl, a first-in-class erythroid maturation agent, has been approved to treat MDS related anemia in ESA-naive patients with LR-MDS.
Sabatolimab binds to the surface of T-cells, releasing the breaks that the tumor applied to the immune system.
For more than 30 years, umbilical cord blood (UCB) has been an important stem cell source for patients with leukemia, lymphoma and MDS
Dr. Sekeres shared with us what he and his MDS colleagues are focusing their research on right now.
Dr. Chandhok is doing important research into improving drug efficacy for underserved populations.
The work Dr. Tinsley Vance is doing is important and will have a big impact on the way we look at patient decision making and our support of caregivers.
Immune system regulators are emerging as significant targets for immunotherapy in hematological malignancies.
BMT “was associated with an increased risk of subsequent malignant neoplasms of the gastrointestinal (GI) tract.”